676 filings
6-K
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
6-K
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
6-K
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
6-K
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
slwu4gw6serlh p9sbp
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
tv2d5k
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
gv7i53i53he9572
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
fodyarnqx2
20 Dec 23
Current report (foreign)
10:39am
6-K
5ujdwu
1 Dec 23
Current report (foreign)
12:19pm
6-K
mrwk3lnws 7vr91en9j8
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
0d0mgolkuo
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
6d8 4ff04gs3xv3l3t4
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
zw63zhepv esked
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
5yno7
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
lh44 d52dd767
27 Sep 23
Current report (foreign)
6:06am
6-K
sj6ukvw7ym7uq 5u5hy
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
w5e2 39ma
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
o2qjbhw07xd1jeo3
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
u0jjn
28 Jul 23
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
9:18am